Comparative study of microencapsulated rat islets implanted in different diabetic models in mice

Area of Science:

• Biomedical Engineering
• Transplantation Immunology
• Endocrinology

Background:

• Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia.
• Islet transplantation is a promising therapeutic strategy for type 1 diabetes.
• Microencapsulation offers a potential method for immune protection of transplanted cells.

Purpose of the Study:

• To evaluate the efficacy of microencapsulated rat islets of Langerhans as a xenograft for correcting hyperglycemia in diabetic mouse models.
• To assess the biocompatibility and long-term stability of alginate-polylysine microcapsules in vivo.

Main Methods:

• Xenotransplantation of microencapsulated rat islets into the peritoneal cavity of diabetic mice.
• Induction of diabetes using streptozotocin (high and low dose) and cyclophosphamide.
• Monitoring of plasma glucose and insulin levels.
• Histological examination of recovered microcapsules.

Main Results:

• Sustained reduction in plasma glucose observed in a subset of mice with high-dose streptozotocin-induced diabetes.
• Partial and transient glycemic control in mice with low-dose streptozotocin-induced diabetes.
• No significant effect in cyclophosphamide-induced diabetic NOD mice.
• Consistent inflammatory reaction surrounding the microcapsules.

Conclusions:

• Microencapsulated rat islets demonstrate potential for improving hyperglycemia in specific diabetic models.
• The efficacy of this xenograft is variable and dependent on the diabetes model.
• The observed inflammatory reaction poses a significant hurdle for successful long-term engraftment and function.